Company Overview and News

1
Ultratech’s resolution plan for Binani Cement submitted at NCLT

2018-06-04 livemint
Kolkata: The resolution professional of Binani Cement Ltd. on Monday submitted the resolution plan of Ultratech Cement Ltd. at the Kolkata bench of the National Company Law Tribunal for its approval even as the tribunal agreed to hear Dalmia Bharat’s objections about Ultratech’s bid.
BINANIIND DALMIABHA 533309 UCLQY UCLQF 532538 500059 ULTRACEMCO

0
Binani Industries Limited - Outcome of Board Meeting

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BINANIIND 500059

1
Binani lenders okay UltraTech acquisition

2018-05-31 freepressjournal.in
New Delhi : The lenders of Binani Cement have issued letter of intent to UltraTech after approving its bid to acquire the company under the bankruptcy code, Aditya Birla group firm said on Wednesday. The Committee of Creditors (CoC) of Binani Cement on May 28 approved the resolution Plan submitted by UltraTech Cement, it said.
BINANIIND UCLQY UCLQF 532538 500059 ULTRACEMCO

1
Binani Cement lenders back UltraTech’s offer

2018-05-28 livemint
Mumbai: UltraTech Cement Ltd’s Rs7,950 crore bid to acquire Binani Cement Ltd has received near-unanimous backing from lenders to the distressed building material maker even as a legal battle reached the country’s top court, two people aware of the development said.
BINANIIND DALMIABHA 533309 UCLQY UCLQF 532538 PRMQY 500059 500302 ULTRACEMCO PEL

4
Binani Cement lenders vote in favour of UltraTech offer

2018-05-28 moneycontrol
The committee of creditors (CoC) for Binani Cement May 28 voted in favour of accepting UltraTech Cement’s Rs 7,950 crore bid.
BINANIIND 500116 DALMIABHA 533309 UCLQY IDBI UCLQF 532538 500059 ULTRACEMCO SBAZ

1
NCLAT refuses to stay Binani Cement insolvency proceedings

2018-05-22 livemint
New Delhi:The National Company Law Appellate Tribunal (NCLAT) on Tuesday refused to stay the corporate insolvency resolution process for Binani Cement Ltd.
BINANIIND UCLQY UCLQF 532538 500059 ULTRACEMCO

0
Binani Ind offers to repay 100% debt of cement unit

2018-05-17 freepressjournal.in
New Delhi : Binani Industries, which holds a 98.4 per cent stake in debt-ridden Binani Cement, on Wednesday offered to clear the 100 per cent claims of creditors at the National Company Law Appellate Tribunal.
BINANIIND 500059

1
Binani Industries offers to pay 100% debt amount of Binani Cement

2018-05-16 livemint
New Delhi: Binani Industries Ltd, the parent of debt-ridden Binani Cement Ltd, told the National Company Law Appellate Tribunal (NCLAT) on Wednesday that it was ready to pay up all the dues of its subsidiary to its financial and operational creditors in two weeks, if the tribunal so permitted.
BINANIIND DALMIABHA 533309 UCLQY UCLQF 532538 500059 ULTRACEMCO

0
Binani Industries Limited - Shareholders meeting

2018-05-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BINANIIND 500059

0
Binani Cement#39;s lenders call off meeting after Dalmia#39;s objection

2018-05-10 moneycontrol
A scheduled meeting of Binani Cement's lenders for Thursday has been postponed after Dalmia Bharat alleged that UltraTech is ineligible from participating in the auction.
BINANIIND DALMIABHA 533309 500059

3
Lenders fret as insolvency cases miss deadlines, hope delays yield better returns

2018-05-04 moneycontrol
The fate of a few of the 12 stressed accounts facing insolvency proceedings — including Essar Steel and Binani Cement — hangs in the balance as court cases are delaying the resolution process beyond the stipulated deadline of 270 days.
ESL BINANIIND KMBKY BHUSANSTL 533264 532538 UCLQF 513216 532778 ULTRACEMCO UTTAMSTL UCLQY KOTAKBANK 500059 500247 LITL 500055

1
It’s Dalmia vs UltraTech again for Binani Cement

2018-05-02 livemint
Kolkata: The Kolkata bench of the bankruptcy court on Wednesday ruled that the lenders of debt-ridden Binani Cement Ltd should consider the revised offer of UltraTech Cement Ltd even as it allowed Dalmia Bharat Ltd, chosen by lenders to take over the indebted cement-maker, to submit new bids, effectively restarting a contest between the two suitors.
BINANIIND DALMIABHA 533309 UCLQY UCLQF 532538 500059 ULTRACEMCO

0
Binani Industries Limited - Resignation

2018-04-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BINANIIND 500059

0
Binani Industries Limited - Appointment

2018-04-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BINANIIND 500059

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...